Bli medlem
Bli medlem

Du är här


Immune Pharmaceuticals: Immune Pharmaceuticals Announces New Data with Bi-Specific Antibody


Platform to be used to generate bi-specific antibodies against
immuno-oncology targets

Immune Pharmaceuticals Inc. (NASDAQ: IMNP) ("Immune" or the "Company") a
clinical-stage company developing novel therapies for the treatment of
immuno-inflammatory diseases and cancer today announced new data with a
novel bi-specific antibody in a poster presentation at IBC's Antibody
Engineering & Therapeutics Conference in San Diego, CA. Immune's poster is
titled "Design and Validation of a Novel Tetravalent IgG1-like Bi- Specific
Antibody Format" and was on display in the exhibit hall December 8-10, 2015
at the San Diego Convention Center.

In this study, Immune described positive developments with a novel platform
for production of tetravalent IgG1-like bi-specific antibodies (bsAb). The
prototype bi-specific antibody retained effector functions and mediated
redirect killing of target cells by cytokine induced killer T cells
demonstrating direct anti-cancer effects in vitro as well as anti-tumor
activity and improved survival in vivo in a mouse xenograft model of
disseminated leukemia. The newly developed platform will be further used to
generate novel bi-specific antibodies against immune-oncology targets.

The poster was presented by Boris Shor, PhD, executive director R&D, Immune
Pharmaceuticals and Jean Kadouche, PhD, a scientific co-founder of Immune
Pharmaceuticals. This work was developed by a collaborative European
consortium (BMC) led by Dr. Kadouche and funded by a European grant.

For poster request, please contact

NEW YORK, December 14, 2015


G.John Mohr
Senior Vice-President, Business Development
IMMUNE Pharmaceuticals, Inc.

The following documents can be retrieved from beQuoted
Immune Pharmaceuticals Pressrelease 2015-12-14.pdf

About Immune Pharmaceuticals:

Immune Pharmaceuticals (NASDAQ: IMNP) applies a personalized approach to
treating and developing novel, highly-targeted antibody therapeutics to
improve the lives of patients with inflammatory diseases and cancer.
Immune's lead product candidate, bertilimumab, is in phase II clinical
development for moderate-to-severe ulcerative colitis as well as for
bullous pemphigoid, an orphan auto-immune dermatological condition. Other
indications being considered for development include atopic dermatitis,
Crohn's disease, severe asthma and NASH (an inflammatory liver disease).
Immune recently expanded its portfolio in immuno-dermatology with topical
nano-formulated cyclosporin A for the treatment of psoriasis and atopic
dermatitis. Immune's oncology pipeline includes, bi-specific antibodies
nanotherapeutics, including NanomAbs®, and several mid-to late stage small
molecules .Immune's non- core pipeline includes AmiKet™, a late clinical
stage drug candidate for the treatment of neuropathic pain. For more
information, visit Immune's website at

Forward-Looking Statements
This news release and any oral statements made with respect to the
information contained in this news release contain forward-looking
statements within the meaning of the Private Securities Litigation Reform
Act of 1995. You are urged to consider statements that include the words
"may," "will," "would," "could," "should," "believes," "estimates,"
"projects," "potential," "expects," "plans," "anticipates," "intends,"
"continues," "forecast," "designed," "goal" or the negative of those words
or other comparable words to be uncertain and forward-looking. Such
forward-looking statements include statements that express plans,
anticipation, intent, contingency, goals, targets, future development and
are otherwise not statements of historical fact. These statements are based
on our current expectations and are subject to risks and uncertainties that
could cause actual results or developments to be materially different from
historical results or from any future results expressed or implied by such
forward-looking statements. Factors that may cause actual results or
developments to differ materially include, but not limited to: the risks
associated with the adequacy of our existing cash resources and our ability
to continue as a going concern; the risks associated with our ability to
continue to meet our obligations under our existing debt agreements; the
risk that clinical trials for bertilimumab or AmiKet™ will not be
successful; the risk that bertilimumab, AmiKet or compounds arising from
our NanomAbs program will not receive regulatory approval or achieve
significant commercial success; the risk that we will not be able to find a
partner to help conduct the Phase III trials for AmiKet on attractive
terms, on a timely basis or at all; the risk that our other product
candidates that appeared promising in early research and clinical trials do
not demonstrate safety and/or efficacy in larger-scale or later-stage
clinical trials; the risk that we will not obtain approval to market any of
our product candidates; the risks associated with dependence upon key
personnel; the risks associated with reliance on collaborative partners and
others for further clinical trials, development, manufacturing and
commercialization of our product candidates; the cost, delays and
uncertainties associated with our scientific research, product development,
clinical trials and regulatory approval process; our history of operating
losses since our inception; the highly competitive nature of our business;
risks associated with litigation; and risks associated with our ability to
protect our intellectual property. These factors and other material risks
are more fully discussed in our periodic reports, including our reports on
Forms 8-K, 10-Q and 10-K and other filings with the U.S. Securities and
Exchange Commission. You are urged to carefully review and consider the
disclosures found in our filings, which are available at or at You are cautioned not to place undue
reliance on any forward- looking statements, any of which could turn out to
be wrong due to inaccurate assumptions, unknown risks or uncertainties or
other risk factors. We expressly disclaim any obligation to publicly update
any forward looking statements contained herein, whether as a result of new
information, future events or otherwise, except as required by law.

Författare BEQ

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.